ArticleJournal of neurology2026
Impact of age on clinical outcomes after endovascular therapy for large ischemic stroke.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endovascular Treatment for Patients Aged ≥80 Years with Large Ischemic Stroke.Clinical interventions in aging · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundThe impact of age on outcomes in patients with large ischemic stroke [defined as Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≤ 5] remains unclear. This study aimed to explore the effect of age on clinical outcomes after endovascular therapy (EVT) for acute anterior circulation large ischemic stroke.
methodsThis subanalysis enrolled patients with acute large ischemic stroke from a prospective multicenter cohort registry from 38 stroke centers across China between November 2021 and February 2023. Patients were stratified into the EVT and standard medical treatment (SMT) groups. The effectiveness outcomes included the distribution of modified Rankin Scale (mRS) score and functional outcomes (mRS 0-2, 0-3, and 0-4) at 90 days. Safety outcomes included 90-day mortality, symptomatic intracranial hemorrhage (ICH) within 48 h, and any ICH.
resultsA total of 745 eligible patients were included in the analysis. Compared with SMT, EVT showed improved 90-day outcomes across different age groups [aged ≤ 65 years, adjusted common odds ratio (acOR): 2.11, 95% confidence interval (CI) 1.16-3.81, P = 0.01; aged 66-79 years, acOR: 1.23, 95% CI 0.79-1.92, P = 0.36; aged ≥ 80 years, acOR: 2.80, 95% CI 1.26-6.22, P = 0.01], while the predicted probabilities of achieving mRS 0-3 decreased and mortality rate increased both in the EVT and SMT groups with advancing age (P
conclusionsIn conclusion, age is a significant predictor of clinical outcomes in anterior circulation large ischemic stroke. While EVT benefits show progressive age-related decline, meaningful advantages persist even in patients aged ≥ 80 years, suggesting that age alone should not contraindicate EVT. However, further validation through large-scale randomized controlled trials is warranted.
Indexed as
Identifiers
42143207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.